CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.
  
  LEARNING OBJECTIVES

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in ovarian cancer (OC), and use the results of these assessments to guide long-term treatment.
  • Evaluate the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and counsel appropriate individuals regarding personalized treatment recommendations.
  • Recognize the recent FDA approval of niraparib as first-line maintenance therapy for patients with advanced OC with or without BRCA mutations, and identify individuals for whom treatment with this agent may be appropriate.
  • Understand the biologic rationale for and available data with the use of PARP inhibitors in combination with anti-angiogenic agents, and discern how this strategy affects current therapeutic algorithms.
  • Appreciate available clinical trial data with PARP inhibition in combination with front-line chemotherapy and then as maintenance treatment for patients with newly diagnosed OC, and evaluate the potential role of this novel therapeutic approach.
  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiple regimen-refractory OC in order to personalize care plans incorporating these agents.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:
  
  Susana Banerjee, MBBS, MA, PhD
  Consultant Medical Oncologist
  Research Lead, Gynecological Cancers
  Reader in Women’s Cancers
  The Institute of Cancer Research
  The Royal Marsden NHS Foundation Trust
  London, United Kingdom
  
  Consulting Agreements, Advisory Boards and Lectures: Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Epsilogen, Genmab, GlaxoSmithKline, ImmunoGen Inc, Merck Serono, Merck Sharp & Dohme Corp, Mersana Therapeutics, Pfizer Inc, Roche Laboratories Inc, Tesaro, A GSK Company; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Tesaro, A GSK Company, Verastem Inc.
  
  Richard T Penson, MD, MRCP
  Associate Professor of Medicine
  Harvard Medical School
  Clinical Director, Medical Gynecologic Oncology
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Care4ward (unpaid), Clovis Oncology, Curio Science, Eisai Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Johnson & Johnson Pharmaceuticals, Lumos Pharma, Merck, Mersana Therapeutics, Nexus Group Global, Pieris Pharmaceuticals Inc, Roche Laboratories Inc, Sutro Biopharma, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company, Vascular Biogenics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Tesaro, A GSK Company, Vascular Biogenics; Data and Safety Monitoring Board/Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP.
  
  Shannon N Westin, MD, MPH
  Associate Professor
  Director, Early Drug Development
  Department of Gynecologic Oncology and Reproductive Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: Agenus Inc, AstraZeneca Pharmaceuticals LP, CIRCULOGENE, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Tesaro, A GSK Company, Zentalis Pharmaceuticals; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bio-Path, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, Novartis, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Xenetic Biosciences Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.
  
  Release date: May 2021
  Expiration date: May 2022